Transplanting the highly sensitized patient: The emory algorithm

被引:174
作者
Bray, R. A.
Nolen, J. D. L.
Larsen, C.
Pearson, T.
Newell, K. A.
Kokko, K.
Guasch, A.
Tso, P.
Mendel, J. B.
Gebel, H. M. [1 ]
机构
[1] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Surg, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Med, Atlanta, GA 30322 USA
关键词
alloantibodies; flow cytometry; HLA; PRA; sensitization;
D O I
10.1111/j.1600-6143.2006.01521.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Renal transplant patients sensitized to HLA antigens comprise nearly one-third of the UNOS wait-list and receive 14% of deceased donor (DD) transplants, a rate half that of unsensitized patients. Between 1999 and 2003, we performed 492 adult renal transplants from DD; 120 patients (similar to 25%) had a panel reactive antibody (PRA) of > 30%, with nearly half (n = 58) having a PRA of > 80%. Our approach is based upon high-resolution solid-phase HLA antibody analysis to identify class I/II antibodies and a 'virtual crossmatch' to predict compatible donor/recipient combinations. Recipients are excluded from the United Network for Organ Sharing match run if donors possess unacceptable antigens. Thus, when sensitized patients appear on the match run, they have a high probability of a negative final crossmatch. Here, we describe our 5-year experience with this approach. Five-year graft survival ranged from 66% to 70% among unsensitized (n = 272), moderately sensitized (PRA < 30%, n = 100) and highly sensitized (> 30% PRA; n = 120) patients, equal to the average national graft survival (65.7%). The application of this approach (the Emory Algorithm) provides a logical and systematic approach to improve the access of sensitized patients to DD organs and promote more equitable allocation to a highly disadvantaged group of patients awaiting renal transplantation.
引用
收藏
页码:2307 / 2315
页数:9
相关论文
共 26 条
[1]   Evolution of HLA antibody detection - Technology emulating biology [J].
Bray, RA ;
Nickerson, PW ;
Kerman, RH ;
Gebel, HM .
IMMUNOLOGIC RESEARCH, 2004, 29 (1-3) :41-53
[2]   THE FLOW CYTOMETRIC CROSSMATCH - DUAL-COLOR ANALYSIS OF T-CELL AND B-CELL REACTIVITIES [J].
BRAY, RA ;
LEBECK, LK ;
GEBEL, HM .
TRANSPLANTATION, 1989, 48 (05) :834-840
[3]   The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome [J].
Claas, FHJ ;
Witvliet, MD ;
Duquesnoy, RJ ;
Persijn, GG ;
Doxiadis, IIN .
TRANSPLANTATION, 2004, 78 (02) :190-193
[4]   Extending options for highly sensitized patients to receive a suitable kidney graft [J].
Doxiadis, IIN ;
Duquesnoy, RJ ;
Claas, FHJ .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (05) :536-540
[5]   HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the algorithm [J].
Duquesnoy, RJ .
HUMAN IMMUNOLOGY, 2002, 63 (05) :339-352
[7]   Sensitization and sensitivity - Defining the unsensitized patient [J].
Gebel, HM ;
Bray, RA .
TRANSPLANTATION, 2000, 69 (07) :1370-1374
[8]   Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk [J].
Gebel, HM ;
Bray, RA ;
Nickerson, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (12) :1488-1500
[9]   Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients [J].
Jordan, SC ;
Vo, A ;
Bunnapradist, S ;
Toyoda, M ;
Peng, A ;
Puliyanda, D ;
Kamil, E ;
Tyan, D .
TRANSPLANTATION, 2003, 76 (04) :631-636
[10]  
Karpinski M, 2001, J AM SOC NEPHROL, V12, P2807, DOI 10.1681/ASN.V12122807